RegenXBio Inc. (($RGNX)) announced an update on their ongoing clinical study. RegenXBio Inc. is conducting a clinical study titled ‘AFFINITY ...
Passage Bio, Inc. (($PASG)) announced an update on their ongoing clinical study. Study Overview: Passage Bio, Inc. is conducting a Phase 1b ...
Long-term follow-up shows 95% success rate, no serious complications in largest ADA-SCID gene therapy study to date ...
Until recently, even the most advanced gene therapies could only be given after a child was born—often racing against time to prevent irreversible damage. In the first part of this series, we explored ...
To solve this critical challenge, he founded Nephrogen in 2022, a biotech startup that uses AI and advanced screening to ...
Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.
The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, after nearly three ...
An experimental genetic therapy can cure most cases of the 'Bubble Boy' disease, ADA-SCID. In the rare disorder, children are ...
Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the first patient has ...
Opus Genetics has shared data on its gene therapy in children with an ultrarare eye disease, setting the biotech up to talk to the FDA about the next steps for the program. North Carolina-based Opus ...
Alison Clare has received funding from the Wellcome Trust and the Medical Research Council. Her position is currently funded by National Institute for Health and Care Research (NIHR) Biomedical ...
Pharmaceutical Technology on MSN
Affinia raises $40m for gene therapy development
Gene therapy company Affinia Therapeutics has raised $40m in a Series C funding round, led by New Enterprise Associates (NEA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback